CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Study sponsor: Curis, Inc. · CRIS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-07Estimated
Enrollment · participants152Estimated
Source updated2026-10-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.